Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Received date: 16 Feb 2017
Accepted date: 07 Apr 2017
Published date: 23 Aug 2017
Copyright
Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has recently been undergoing rapid development. However, there are still some major challenges, including precise tumor targeting to avoid off-target or “on-target/off-tumor” toxicity, adequate T cell infiltration and migration to solid tumors and T cell proliferation and persistence across the physical and biochemical barriers of solid tumors. In this review, we focus on the primary challenges and strategies to design safe and effective CAR T cells, including using novel cutting-edge technologies for CAR and vector designs to increase both the safety and efficacy, further T cell modification to overcome the tumorassociated immune suppression, and using gene editing technologies to generate universal CAR T cells. All these efforts promote the development and evolution of CAR T cell therapy and move toward our ultimate goal—curing cancer with high safety, high efficacy, and low cost.
Hua Li , Yangbing Zhao . Increasing the safety and efficacy of chimeric antigen receptor T cell therapy[J]. Protein & Cell, 2017 , 8(8) : 573 -589 . DOI: 10.1007/s13238-017-0411-9
1 |
AhmedN, BrawleyVS, HegdeM, RobertsonC, GhaziA, GerkenC, LiuE, DakhovaO, AshooriA, CorderA
|
2 |
Alvarez-RuedaN, DesselleA, CochonneauD, ChaumetteT, ClemenceauB, LeprieurS, BougrasG, SupiotS, MussiniJM, BarbetJ
|
3 |
AnkriC, ShamalovK, Horovitz-FriedM, MauerS, CohenCJ (2013) Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.J Immunol191:4121–4129
|
4 |
BarrettDM, TeacheyDT, GruppSA (2014) Toxicity management for patients receiving novel T-cell engaging therapies.Curr Opin Pediatr26:43–49
|
5 |
BeaneJD, LeeG, ZhengZ, MendelM, Abate-DagaD, BharathanM, BlackM, GandhiN, YuZ, ChandranS
|
6 |
BeattyGL, HaasAR, MausMV, TorigianDA, SoulenMC, PlesaG, ChewA, ZhaoY, LevineBL, AlbeldaSM
|
7 |
BerdienB, MockU, AtanackovicD, FehseB (2014) TALENmediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer.Gene Ther21:539–548
|
8 |
BoniniC, FerrariG, VerzelettiS, ServidaP, ZapponeE, RuggieriL, PonzoniM, RossiniS, MavilioF, TraversariC
|
9 |
BrownCE, AlizadehD, StarrR, WengL, WagnerJR, NaranjoA, OstbergJR, BlanchardMS, KilpatrickJ, SimpsonJ
|
10 |
CarpenitoC, MiloneMC, HassanR, SimonetJC, LakhalM, SuhoskiMM, Varela-RohenaA, HainesKM, HeitjanDF,AlbeldaSM
|
11 |
CarpenterRO, EvbuomwanMO, PittalugaS, RoseJJ, RaffeldM, YangS,GressREHakimFT, KochenderferJN (2013) B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.Clin Cancer Res19:2048–2060
|
12 |
CarusoHG, HurtonLV, NajjarA, RushworthD, AngS, OlivaresS, MiT, SwitzerK, SinghH, HulsH
|
13 |
CherkasskyL, MorelloA, Villena-VargasJ, FengY, DimitrovDS, JonesDR, SadelainM, AdusumilliPS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.J Clin Investig126:3130–3144
|
14 |
ChinnasamyD, YuZ, TheoretMR, ZhaoY, ShrimaliRK, MorganRA, FeldmanSA, RestifoNP, RosenbergSA (2010) Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.J Clin Investig120:3953–3968
|
15 |
ChmielewskiM, AbkenH (2015) TRUCKs: the fourth generation of CARs.Expert Opin Biol Ther15:1145–1154
|
16 |
ChmielewskiM, HombachA, HeuserC, AdamsGP, AbkenH (2004) T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.J Immunol173:7647–7653
|
17 |
ChmielewskiM, HombachAA, AbkenH (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.Immunol Rev257:83–90
|
18 |
CiceriF, BoniniC, StanghelliniMT, BondanzaA, TraversariC, SalomoniM, TurchettoL, ColombiS, BernardiM, PeccatoriJ
|
19 |
CongL, RanFA, CoxD, LinS, BarrettoR, HabibN, HsuPD, WuX, JiangW, MarraffiniLA
|
20 |
CraddockJA, LuA, BearA, PuleM, BrennerMK, RooneyCM, FosterAE (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.J Immunother33:780–788
|
21 |
CurranMA, MontalvoW, YagitaH, AllisonJP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.Proc Natl Acad Sci USA107:4275–4280
|
22 |
EshharZ, WaksT, GrossG, SchindlerDG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.Proc Natl Acad Sci USA90:720–724
|
23 |
EyquemJ, Mansilla-SotoJ, GiavridisT, van der StegenSJ, HamiehM, CunananKM, OdakA, GonenM, SadelainM (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.Nature543:113–117
|
24 |
FaitschukE, HombachAA, FrenzelLP, WendtnerCM, AbkenH (2016) Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells.Blood128:1711–1722
|
25 |
FengK, GuoY, DaiH, WangY, LiX, JiaH, HanW (2016) Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.Sci China Life Sci59:468–479
|
26 |
FinneyHM, LawsonAD, BebbingtonCR, WeirAN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.J Immunol161:2791–2797
|
27 |
FitzGeraldDJ, WayneAS, KreitmanRJ, PastanI (2011) Treatment of hematologic malignancies with immunotoxins and antibodydrug conjugates.Cancer Res71:6300–6309
|
28 |
GruppSA, KalosM, BarrettD, AplencR, PorterDL, RheingoldSR, TeacheyDT, ChewA, HauckB, WrightJF
|
29 |
GubinMM, ZhangX, SchusterH, CaronE, WardJP, NoguchiT, IvanovaY, HundalJ, ArthurCD, KrebberWJ
|
30 |
HasoW, LeeDW, ShahNN, Stetler-StevensonM, YuanCM, PastanIH, DimitrovDS, MorganRA, FitzGeraldDJ, BarrettDM
|
31 |
HongH, StastnyM, BrownC, ChangWC, OstbergJR, FormanSJ, JensenMC (2014) Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.J Immunother37:93–104
|
32 |
HoyosV, SavoldoB, QuintarelliC, MahendravadaA, ZhangM, VeraJ, HeslopHE, RooneyCM, BrennerMK, DottiG (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.Leukemia24:1160–1170
|
33 |
HudecekM, SchmittTM, BaskarS, Lupo-StanghelliniMT, NishidaT, YamamotoTN, BleakleyM, TurtleCJ, ChangWC, GreismanHA
|
34 |
HudecekM, Lupo-StanghelliniMT, KosasihPL, SommermeyerD, JensenMC, RaderC, RiddellSR (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor Tcells.Clin Cancer Res19:3153–3164
|
35 |
JohnsonLA, SchollerJ, OhkuriT, KosakaA, PatelPR, McGettiganSE, NaceAK, DentchevT, ThekkatP, LoewA
|
36 |
KershawMH, WestwoodJA, ParkerLL, WangG, EshharZ, MavroukakisSA, WhiteDE, WunderlichJR, CanevariS, Rogers-FreezerL
|
37 |
KlossCC, CondominesM, CartellieriM, BachmannM, SadelainM (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.Nat Biotechnol31:71–75
|
38 |
LamersCH, SleijferS, VultoAG, KruitWH, KliffenM, DebetsR, GratamaJW, StoterG, OosterwijkE (2006a) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.J Clin Oncol24:e20–e22
|
39 |
LamersCH, van ElzakkerP, LangeveldSC, SleijferS, GratamaJW (2006b) Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient’s T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.Cytotherapy8:542–553
|
40 |
LanitisE, PoussinM, KlattenhoffAW, SongD, SandaltzopoulosR, JuneCH, PowellDJ Jr (2013) Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.Cancer Immunol Res1:43–53
|
41 |
LinetteGP, StadtmauerEA, MausMV, RapoportAP, LevineBL, EmeryL, LitzkyL, BaggA, CarrenoBM, CiminoPJ
|
42 |
LiuX, JiangS, FangC, YangS, OlalereD, PequignotEC, CogdillAP, LiN, RamonesM, GrandaB
|
43 |
LiuX, RanganathanR, JiangS, FangC, SunJ, KimS, NewickK, LoA, JuneCH, ZhaoY
|
44 |
LiuX, ZhangY, ChengC, ChengAW, ZhangX, LiN, XiaC, WeiX, LiuX, WangH(2016b) CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells.Cell Res27:154–157
|
45 |
LouisCU, SavoldoB, DottiG, PuleM, YvonE, MyersGD, RossigC, RussellHV, DioufO, LiuE
|
46 |
LuYC, RobbinsPF (2016) Cancer immunotherapy targeting neoantigens.Semin Immunol28:22–27
|
47 |
MacLeodDT, AntonyJ, MartinAJ, MoserRJ, HekeleA, WetzelKJ, BrownAE, TriggianoMA, HuxJA, PhamCD
|
48 |
MaherJ, BrentjensRJ, GunsetG, RiviereI, SadelainM(2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.Nat Biotechnol20:70–75
|
49 |
MardirosA, Dos SantosC, McDonaldT, BrownCE, WangX, BuddeLE, HoffmanL, AguilarB, ChangWC, BretzlaffW
|
50 |
MaudeSL, FreyN, ShawPA, AplencR, BarrettDM, BuninNJ, ChewA, GonzalezVE, ZhengZ, LaceySF
|
51 |
MausMV, HaasAR, BeattyGL, AlbeldaSM, LevineBL, LiuX, ZhaoY, KalosM, JuneCH (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.Cancer Immunol Res1:26–31
|
52 |
MorganRA, YangJC, KitanoM, DudleyME, LaurencotCM, RosenbergSA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Mol Ther18:843–851
|
53 |
MorganRA, ChinnasamyN, Abate-DagaD, GrosA, RobbinsPF, ZhengZ, DudleyME, FeldmanSA, YangJC, SherryRM
|
54 |
NewickK, O’BrienS, SunJ, KapoorV, MaceykoS, LoA, PureE, MoonE, AlbeldaSM (2016) Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization.Cancer Immunol Res4:541–551
|
55 |
OliveiraG, GrecoR, Lupo-StanghelliniMT, VagoL, BoniniC (2012) Use of TK-cells in haploidentical hematopoietic stem cell transplantation.Curr Opin Hematol19:427–433
|
56 |
OrenR, Hod-MarcoM, Haus-CohenM, ThomasS, BlatD, DuvshaniN, DenkbergG, ElbazY, BenchetritF, EshharZ
|
57 |
ParkJR, DigiustoDL, SlovakM, WrightC, NaranjoA, WagnerJ, MeechoovetHB, BautistaC, ChangWC, OstbergJR
|
58 |
ParkhurstMR, YangJC, LanganRC, DudleyME, NathanDA, FeldmanSA, DavisJL, MorganRA, MerinoMJ, SherryRM
|
59 |
PhilipB, KokalakiE, MekkaouiL, ThomasS, StraathofK, FlutterB, MarinV, MarafiotiT, ChakravertyR, LinchD
|
60 |
PorterDL, LevineBL, KalosM, BaggA, JuneCH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med365:725–733
|
61 |
PorterDL, HwangWT, FreyNV, LaceySF, ShawPA, LorenAW, BaggA, MarcucciKT, ShenA, GonzalezV
|
62 |
PoseyAD Jr, SchwabRD, BoesteanuAC, SteentoftC, MandelU, EngelsB, StoneJD, MadsenTD, SchreiberK, HainesKM
|
63 |
ProsserME, BrownCE, ShamiAF, FormanSJ, JensenMC (2012) Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.Mol Immunol51:263–272
|
64 |
ProvasiE, GenoveseP, LombardoA, MagnaniZ, LiuPQ, ReikA, ChuV, PaschonDE, ZhangL, KuballJ
|
65 |
QasimW, ZhanH, SamarasingheS, AdamsS, AmroliaP, StaffordS, ButlerK, RivatC, WrightG, SomanaK
|
66 |
RafiqS, PurdonTJ, DaniyanAF, KoneruM, DaoT, LiuC, ScheinbergDA, BrentjensRJ (2016) Optimized T-cell receptormimic (TCRm) chimeric antigen receptor T-cells directed towards the intracellular Wilms Tumor 1 antigen.Leukemia.
|
67 |
ReiterY, Di CarloA, FuggerL, EngbergJ, PastanI (1997) Peptidespecific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.Proc Natl Acad Sci USA94:4631–4636
|
68 |
RenJ, LiuX, FangC, JiangS, JuneCH, ZhaoY (2016) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition.Clin Cancer Res.
|
69 |
RobbinsPF, LuYC, El-GamilM, LiYF, GrossC, GartnerJ, LinJC, TeerJK, CliftenP, TycksenE
|
70 |
RobertC, LongGV, BradyB, DutriauxC, MaioM, MortierL, HasselJC, RutkowskiP, McNeilC, Kalinka-WarzochaE
|
71 |
RoybalKT, RuppLJ, MorsutL, WalkerWJ, McNallyKA, ParkJS, LimWA (2016a) Precision tumor recognition by T cells with combinatorial antigen-sensing circuits.Cell164:770–779
|
72 |
RoybalKT, WilliamsJZ, MorsutL, RuppLJ, KolinkoI, ChoeJH, WalkerWJ, McNallyKA, LimWA (2016b) Engineering Tcells with customized therapeutic response programs using synthetic notch receptors.Cell167(419–432):e416
|
73 |
SakemuraR, TerakuraS, WatanabeK, JulamaneeJ, TakagiE, MiyaoK, KoyamaD, GotoT, HanajiriR, NishidaT
|
74 |
SakuishiK, ApetohL, SullivanJM, BlazarBR, KuchrooVK, AndersonAC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.J Exp Med207:2187–2194
|
75 |
SampsonJH, ChoiBD, Sanchez-PerezL, SuryadevaraCM, SnyderDJ, FloresCT, SchmittlingRJ, NairSK, ReapEA, NorbergPK
|
76 |
SchubertML, HuckelhovenA, HoffmannJM, SchmittA, WuchterP, SellnerL, HofmannS, HoAD, DregerP, SchmittM (2016) Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation.Hum Gene Ther27(10):758–771
|
77 |
SchumacherTN, SchreiberRD (2015) Neoantigens in cancer immunotherapy.Science348:69–74
|
78 |
SinghJA, BegS, Lopez-OlivoMA (2011) Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.J Rheumatol38:10–20
|
79 |
SinghN, LiuX, HulittJ, JiangS, JuneCH, GruppSA, BarrettDM, ZhaoY (2014) Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.Cancer Immunol Res2:1059–1070
|
80 |
SmithMR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.Oncogene22:7359–7368
|
81 |
SuzukiM, CheungNK (2015) Disialoganglioside GD2 as a therapeutic target for human diseases.Expert Opin Ther Targets19:349–362
|
82 |
TaubeJM, KleinA, BrahmerJR, XuH, PanX, KimJH, ChenL, PardollDM, TopalianSL, AndersRA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res20:5064–5074
|
83 |
TillBG, JensenMC, WangJ, ChenEY, WoodBL, GreismanHA, QianX, JamesSE, RaubitschekA, FormanSJ
|
84 |
TillBG, JensenMC, WangJ, QianX, GopalAK, MaloneyDG, LindgrenCG, LinY, PagelJM, BuddeLE
|
85 |
TopalianSL, SznolM, McDermottDF, KlugerHM, CarvajalRD, SharfmanWH, BrahmerJR, LawrenceDP, AtkinsMB, PowderlyJD
|
86 |
TorikaiH, ReikA, SoldnerF, WarrenEH, YuenC, ZhouY, CrosslandDL, HulsH, LittmanN, ZhangZ
|
87 |
TranE, TurcotteS, GrosA, RobbinsPF, LuYC, DudleyME, WunderlichJR, SomervilleRP, HoganK, HinrichsCS
|
88 |
TuguesS, BurkhardSH, OhsI, VrohlingsM, NussbaumK, Vom BergJ, KuligP, BecherB(2015) New insights into IL-12-mediated tumor suppression.Cell Death Differ22:237–246
|
89 |
ValtonJ, GuyotV, MarechalA, FilholJM, JuilleratA, DuclertA, DuchateauP, PoirotL (2015) A Multidrug-resistant Engineered CAR T cell for allogeneic combination immunotherapy.Mol Ther23:1507–1518
|
90 |
VeraJ, SavoldoB, VigourouxS, BiagiE, PuleM, RossigC, WuJ, HeslopHE, RooneyCM, BrennerMK
|
91 |
WangX, ChangWC, WongCW, ColcherD, ShermanM, OstbergJR, FormanSJ, RiddellSR, JensenMC (2011) A transgeneencoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.Blood118:1255–1263
|
92 |
WatanabeK, TerakuraS, MartensAC, van MeertenT, UchiyamaS, ImaiM, SakemuraR, GotoT, HanajiriR, ImahashiN
|
93 |
WilkieS, van SchalkwykMC, HobbsS, DaviesDM, van der StegenSJ, PereiraAC, BurbridgeSE, BoxC, EcclesSA, MaherJ (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.J Clin Immunol32:1059–1070
|
94 |
WolchokJD, HodiFS, WeberJS, AllisonJP, UrbaWJ, RobertC, O’DaySJ, HoosA, HumphreyR, BermanDM
|
95 |
WuCY, RoybalKT, PuchnerEM, OnufferJ, LimWA (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.Science350:aab4077
|
96 |
YarchoanM, JohnsonBA III, LutzER, LaheruDA, JaffeeEM (2017) Targeting neoantigens to augment antitumour immunity.Nat Rev Cancer17:209–222
|
97 |
ZahE, LinMY, Silva-BenedictA, JensenMC, ChenYY (2016) Tcells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells.Cancer Immunol Res4:498–508
|
98 |
ZhangL, KerkarSP, YuZ, ZhengZ, YangS, RestifoNP, RosenbergSA, MorganRA (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Mol Ther19:751–759
|
99 |
ZhangL, MorganRA, BeaneJD, ZhengZ, DudleyME, KassimSH, NahviAV, NgoLT, SherryRM, PhanGQ
|
100 |
ZhangW-Y, WangY, GuoY-L, DaiH-R, YangQ-M, ZhangY-J, ZhangY, ChenM-X, WangC-M, FengK-C
|
101 |
ZhaoY, ZhengZ, CohenCJ, GattinoniL, PalmerDC, RestifoNP, RosenbergSA, MorganRA (2006) High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.Mol Ther13:151–159
|
102 |
ZhaoY, WangQJ, YangS, KochenderferJN, ZhengZ, ZhongX, SadelainM, EshharZ, RosenbergSA, MorganRA (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.J Immunol183:5563–5574
|
103 |
ZhaoY, MoonE, CarpenitoC, PaulosCM, LiuX, BrennanAL, ChewA, CarrollRG, SchollerJ, LevineBL
|
104 |
ZhuX, PrasadS, GaedickeS, HettichM, FiratE, NiedermannG (2015) Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.Oncotarget6:171–184
|
/
〈 | 〉 |